- Home
- SLI vs PHAT Comparison
SLI vs PHAT Comparison
Compare SLI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLI | PHAT |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SLI | PHAT |
|---|---|---|
| Price | $4.22 | $12.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.25 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 3.4M | 988.1K |
| Earning Date | 11-10-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $147,190,000.00 |
| Revenue This Year | N/A | $221.87 |
| Revenue Next Year | N/A | $80.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $1.08 | $2.21 |
| 52 Week High | $6.40 | $18.31 |
Technical Indicators
Market Signals| Indicator | SLI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 35.59 |
| Support Level | $3.97 | $12.22 |
| Resistance Level | $4.42 | $13.18 |
| Average True Range (ATR) | 0.40 | 0.80 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 12.07 | 7.91 |
Price Performance
Historical ComparisonAbout SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.